Concerns Over Abortion Pill Access and Telemedicine Practices
Advocates for the availability of abortion pills argue that these drugs represent essential medical care, labeling them as a straightforward healthcare intervention. They often suggest that there’s no reason to be concerned about potential rollbacks of safety protocols by the Food and Drug Administration (FDA).
However, it seems that the process has transformed into online commerce rather than authentic telemedicine. A ruling made on April 7 allowed the FDA to temporarily halt a case contesting access to mifepristone, a drug commonly used in abortions, while recognizing the risks associated with these medications.
As a board-certified OB-GYN, I’ve seen the potential of effective telemedicine, especially in areas where medical resources are scarce. It’s crucial, I think, that both pro-life and pro-choice medical professionals agree on the fact that having access shouldn’t overshadow other essential care requirements, particularly for a medication that necessitates some form of clinician interaction.
True telemedicine still requires patients to consult with a clinician. One benefit is that it allows patients to connect with their healthcare providers without having to visit an office, which can reduce barriers to care for many individuals.
Yet, this only functions well if there’s genuine medical oversight and if the conditions needing treatment don’t require an in-person assessment to evaluate the patient’s situation thoroughly.
If abortion drugs are going to be dispensed through telemedicine, we must assume certain standards are met. Firstly, there should be a live interaction with a qualified clinician or at least a thorough review of the patient’s clinical data before prescribing these medications. Additionally, patient identity and age need to be verified, and appropriate screenings should be conducted to identify any potentially serious health risks, as well as confirming the patient’s gestational age and providing context-specific counseling.
These conditions are not trivial; they align with guidance from the American College of Obstetricians and Gynecologists (ACOG), which advises confirming pregnancy and estimating gestational age, discussing potential signs of complications, and offering support in cases where a medication abortion doesn’t succeed.
These are critical considerations, as they can mean life or death, particularly for some of my patients. In light of this, there has been an investigation into companies manufacturing these drugs, and legislation has been proposed to protect women from associated risks.
Providers of abortion pills assert that a qualified medical professional evaluates any patient’s information prior to issuing a prescription.
To explore this claim, I visited a “Plan C” website to verify if ACOG’s recommendations and the site’s assertions were being followed in the processes involved in obtaining abortion medications via telemedicine.
For my inquiry, I pretended to be a 13-year-old with an IUD, taking blood-thinning medications, suffering from anemia, having had three prior C-sections, and a history of ectopic pregnancy. This intentionally absurd combination should have raised immediate red flags.
Despite the significant risks related to taking mifepristone under these conditions, I quickly received a payment request and confirmation of my address to have the pills shipped, just two minutes after sending the form. This was surprising, considering the website had assured me that I wouldn’t receive anything until a healthcare professional reviewed my information.
The screening didn’t include any steps to verify that I was actually ordering the medication for myself, nor did it require basic identification. I was allowed to proceed after only acknowledging that I had read the associated warnings, and the website even permitted me to modify my answers and continue ordering after being warned of various responses.
In the end, I was prompted to sign an agreement stating I understood potential side effects that hadn’t been detailed before, including infection risks, and I checked a box affirming I had discussed these with a healthcare provider.
Throughout this process, I hadn’t spoken to anyone—let alone a physician—whom I could reach out to if complications arose. Furthermore, there was no requirement for a doctor’s note or the name of my physician.
It felt as though the FDA and ACOG’s safety protocols simply ceased to apply once abortion pills became available online.
Patients certainly deserve better than this.
Allowing an anonymous entity to manage a website distributing these drugs to individuals who clearly should not receive them is not merely negligent—it might even be criminal.
Ultimately, the responsibility is placed on the young girl or woman who believes that institutions like the FDA and ACOG are ensuring safe access to care. Normally, this comprehensive oversight would be provided by a healthcare professional who engages in detailed discussions with patients about their specific risks, answers questions, and offers ongoing support. Eliminating doctors and safety measures from the process is a stark deviation from what healthcare should be.
Women and girls facing tough situations in all 50 states aren’t receiving actual healthcare through telemedicine—they’re just getting a bill.
